Resmed Stock Price, News & Analysis

ResMed (NYSE: RMD, ASX: RMD) has expanded its board of directors to 11 members by appointing Christopher DelOrefice, the current CFO of Becton, Dickinson and Company (BD). DelOrefice brings over 30 years of strategic and operational finance expertise to ResMed's board. He will also serve on the board's audit committee. DelOrefice's appointment is effective immediately, and he will stand for re-election at ResMed's annual meeting on November 21, 2024.

Prior to joining BD, DelOrefice held various leadership roles at Johnson & Johnson, including vice president of investor relations and CFO of J&J's consumer and medical device business segments for North America. His experience also includes positions at AstraZeneca, AET Films, and Ametek. ResMed's CEO, Mick Farrell, praised DelOrefice's achievements and leadership capabilities, noting that his financial experience in healthcare and medical technology will complement the existing board members.

ResMed Inc. (NYSE: RMD, ASX: RMD) reported strong Q4 2024 results with year-over-year revenue growth of 9% to $1.2 billion. Key highlights include:

- Gross margin improved 350 bps to 58.5%
- Income from operations increased 38%
- Operating cash flow of $440 million
- Diluted EPS of $1.98; non-GAAP diluted EPS of $2.08
- Quarterly dividend increased 10% to $0.53 per share

For the full fiscal year 2024, ResMed achieved:

- Revenue growth of 11% to $4.7 billion
- Gross margin improvement of 90 bps to 56.7%
- Income from operations increase of 17%
- Operating cash flow of $1.4 billion
- Diluted EPS of $6.92; non-GAAP diluted EPS of $7.72

The company reported strong performance across all sectors, driven by high demand for its products and software solutions.

ResMed (NYSE: RMD, ASX: RMD) announces it will release its fourth quarter fiscal year 2024 earnings on August 1, 2024, after the NYSE closes. Management will host a webcast to discuss the financial and operational results. Investors and stakeholders will gain insights into the company's performance and future outlook.

ResMed presented 13 new clinical studies at SLEEP 2024, highlighting the effectiveness of PAP therapy for Obstructive Sleep Apnea (OSA) and comorbid insomnia (COMISA). Key findings include a 31% reduction in hospitalizations and a 23% decrease in ER visits among COMISA patients adhering to PAP therapy. The research also revealed a 17% prevalence of insomnia in adults across North America, Latin America, and the Caribbean, and higher rates of depression in women with OSA. The studies underscore the importance of sleep health and PAP therapy in improving patient outcomes.

New research supported by ResMed, presented at the American Thoracic Society (ATS) 2024 International Conference, highlights the effectiveness of Positive Airway Pressure (PAP) therapy in reducing risks of death and hospitalization in patients with obstructive sleep apnea (OSA). Notable findings include a 37% reduction in mortality for PAP-treated OSA patients and a projection that OSA prevalence in the U.S. will rise by 26.7% among adults aged 30-70 by 2050. Additional studies reveal that adherence to GLP-1 medications correlates with higher PAP therapy usage, and adaptive servo-ventilation (ASV) therapy improves quality of life for patients with treatment-emergent central sleep apnea (TE-CSA) and opioid-induced central sleep apnea. The research underscores the critical role of PAP therapy in managing sleep disorders and improving cardiovascular health outcomes.

ResMed will present 26 abstracts at the American Thoracic Society (ATS) 2024 conference in San Diego, highlighting the increasing prevalence of obstructive sleep apnea (OSA) and the critical role of Positive Airway Pressure (PAP) therapy. Key sessions include studies on the impact of PAP therapy on hospitalization, mortality in OSA patients, and the prevalence of OSA into 2050. The event will showcase digital innovations and patient-centric approaches in respiratory care, featuring the latest ResMed products like the AirCurve 11 Bilevel Devices and the AirFit F40 CPAP mask.

ResMed (RMD) announced its participation in the RBCCM Global Healthcare Conference with key company executives discussing key topics. The event will be held on May 14, 2024, at InterContinental New York Barclay. More details and webcast access are available on ResMed's investor relations website.